01/03/2026
One Year of HHS Under Secretary Kennedy: An Assessment of Outcomes
It has been just over a year since Robert F Kennedy Jr was confirmed as Secretary of the US Department of Health and Human Services (HHS). His initial address to staff outlined goals of restoring public trust through transparency, unbiassed science, and ethical leadership.
A review of the subsequent twelve months published by the Lancet, indicates a significant divergence from those objectives. https://tinyurl.com/53y7xbck
The operational changes within HHS have been substantial. The department rescinded a long-standing policy that allowed for public comment on new regulations, reducing stakeholder input. There have been numerous staff departures among advisors and experts, and a reported whistleblower was dismissed. Policy announcements have occasionally been communicated through platforms with restricted access.
These administrative shifts have coincided with notable changes in scientific and public health priorities:
Research Direction: The National Institutes of Health (NIH) discontinued certain programs, including studies on the health effects of air pollution. The Food and Drug Administration (FDA) withdrew previously issued warnings regarding products promoted for unapproved uses.
Guidance and Recommendations: Federal guidelines on various health topics have been revised in ways that diverge from long-standing scientific consensus. This has contributed to 26 states opting to deviate from the Centers for Disease Control and Prevention's (CDC) standard vaccine guidance.
Grant Oversight: The CDC awarded a $1.6 million grant for an international vaccine study that has raised ethical questions among researchers, citing concerns about exposing participants to preventable risks.
The management of public health data has also been affected. Thousands of datasets, including those tracking drug overdoses, maternal mortality, and food security, are currently unavailable to the public.
This limits the capacity of researchers and public health officials, both in the US and internationally, to monitor emerging trends and prepare for potential health crises. This data gap is occurring alongside the current spread of communicable diseases, including measles, pertussis, and the recent identification of a human case of H5N5 avian influenza.
From a broader international perspective, the changes at US health agencies have consequences well beyond American borders. The US has historically been a central contributor to global health research, disease surveillance, and scientific collaboration. It has attracted the best and brightest global researchers to its universities and laboratories which are now feeling the loss as that expertise seeks better and more inviting locations.
The current reduction in publicly available data and the shift in research priorities may affect the ability of the US and other nations to inform public health strategies. International partners who rely on collaboration with the NIH, FDA, and CDC face a period of uncertainty regarding the accuracy, consistency and accessibility of US scientific output. When questioned by Congress on these matters, Secretary Kennedy's responses have been described by observers as evasive.
With calls for his resignation reportedly numbering in the thousands, the focus now turns to Congress. The legislative branch's oversight role presents a mechanism to assess whether the current trajectory of HHS aligns with its mandate to protect public health, or whether alternative measures are necessary to address the long-term implications for science and health security in the US and abroad. AHCRA agrees with the Lancet.